To further examine whether ACVRL1 inhibition could increase sensitivity to Regorafenib treatment in CRC, we treated HCT15 cells with vehicle (DMSO, concentration<1/1000), Regorafenib, ML347(a highly selective ACVRL1 inhibitor), and Regorafenib combined with ML347. The gene discussed is ACVRL1; the disease is colorectal carcinoma.